166 related articles for article (PubMed ID: 15850988)
1. Current pharmacological treatment for fibrous dysplasia and perspectives for the future.
Chapurlat R
Joint Bone Spine; 2005 May; 72(3):196-8. PubMed ID: 15850988
[No Abstract] [Full Text] [Related]
2. Prevention and treatment of osteoporosis.
Lloyd M
Clin Med (Lond); 2001; 1(2):155-6. PubMed ID: 11333463
[No Abstract] [Full Text] [Related]
3. [To treat effectively without delay. The data on fractures decisive].
MMW Fortschr Med; 2003 May; 145(21):56-7. PubMed ID: 12845873
[No Abstract] [Full Text] [Related]
4. Risedronate released for Paget's disease.
Am J Health Syst Pharm; 1998 May; 55(10):984. PubMed ID: 9606445
[No Abstract] [Full Text] [Related]
5. Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.
Papapoulos SE
Ann Med Interne (Paris); 2000 Oct; 151(6):504-10. PubMed ID: 11104931
[No Abstract] [Full Text] [Related]
6. Risedronate: a new oral bisphosphonate.
Roll KT
Clin Ther; 2002 May; 24(5):835-6. PubMed ID: 12075950
[No Abstract] [Full Text] [Related]
7. Risedronate prevents hip fractures, but who should get therapy?
Deal CL
Cleve Clin J Med; 2002 Dec; 69(12):964, 968-70, 973-6. PubMed ID: 12546269
[TBL] [Abstract][Full Text] [Related]
8. Fracture protection in osteoporosis with risedronate.
Boonen S; Vanderschueren D
Hosp Med; 2004 Sep; 65(9):535-40. PubMed ID: 15449490
[No Abstract] [Full Text] [Related]
9. Osteoporosis: which current treatments reduce fracture risk?
Baran DT
Cleve Clin J Med; 2000 Oct; 67(10):701-3. PubMed ID: 11060956
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates.
Diez-Perez A
Maturitas; 2002 Aug; 43 Suppl 1():S19-26. PubMed ID: 12361885
[No Abstract] [Full Text] [Related]
11. Risedronate for the prevention and treatment of postmenopausal osteoporosis: results from recent clinical trials.
Watts NB
Osteoporos Int; 2001 Dec; 12 Suppl 3():S17-22. PubMed ID: 11846337
[TBL] [Abstract][Full Text] [Related]
12. Evidence-based medicine: putting theory into practice.
Irani M
Hosp Med; 2001 Mar; 62(3):164-8. PubMed ID: 11291467
[TBL] [Abstract][Full Text] [Related]
13. Prediction and assessment of the response of Paget's disease to bisphosphonate treatment.
Hosking DJ
Bone; 1999 May; 24(5 Suppl):69S-71S. PubMed ID: 10321933
[TBL] [Abstract][Full Text] [Related]
14. [Alternatives to hormonal treatment for the prevention of postmenopausal osteoporosis: the bisphosphonates].
Trémollières F
Gynecol Obstet Fertil; 2001 Nov; 29(11):846-52. PubMed ID: 11770280
[No Abstract] [Full Text] [Related]
15. Gastroenterologists and choosing the right bisphosphonate.
Leder BZ; Kronenberg HM
Gastroenterology; 2000 Sep; 119(3):866-9. PubMed ID: 10982780
[No Abstract] [Full Text] [Related]
16. The use of risedronate in Paget's disease.
Miller PD
Bone; 1999 May; 24(5 Suppl):91S-92S. PubMed ID: 10321937
[No Abstract] [Full Text] [Related]
17. Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist?
Compston JE
Bone; 2000 Dec; 27(6):765-8. PubMed ID: 11113386
[No Abstract] [Full Text] [Related]
18. Prevention and treatment of osteoporosis.
Prestwood KM; Raisz LG
Clin Cornerstone; 2000; 2(6):34-44. PubMed ID: 10938990
[TBL] [Abstract][Full Text] [Related]
19. Risedronate treatment and extended fracture protection in postmenopausal women.
Harris ST
Clin Exp Rheumatol; 2001; 19(6):625-6. PubMed ID: 11791630
[No Abstract] [Full Text] [Related]
20. Risedronate: a new oral bisphosphonate.
Umland EM; Boyce EG
Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
